Laser Treatment for Pain from Chemotherapy in Cancer Survivors

Inclusion Criteria: * Male or female aged 18 years minimum; * Patient with cancer, whatever the location; * Patient with significant NP defined as a score of 4 at the clinician-rated DN4 ; * Patient with a NP for at least 3 months after the end of an adjuvant or neo-adjuvant chemotherapy; * Women of childbearing potential must have a pregnancy urinary test within a maximum of 7 days before starting the study treatment. A negative result must be documented before study treatment is started. Women without reproductive potential are postmenopausal women or women who have undergone permanent sterilisation (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy); * Effective contraception for women of childbearing age * Patient having signed informed consent prior to any study procedure; * Patient affiliated to a French social protection system; * Patient sufficiently fluent in French to complete questionnaires, as the investigator clinical discretion. Exclusion Criteria: * Patient unable to come twice a week to the investigator center; * Patient unable to sit for a 30-minutes period; * Patient with an open wound or ulcer on the treatment area; * Patient whose diagnosis of peripheral neuropathy is due to another cause (n.b., diabetes without neuropathy will not be a specific exclusion); * Patient with uncontrolled psychiatric illness or neurocognitive impairment that may interfere with assessments, as the investigator clinical discretion; * Patient whose estimated life expectancy is less than 3 months, as estimated by a clinical investigator; * Patient using another concurrent non-pharmacological intervention or complementary therapy for neuropathy during the study; * Patient who has been treated with CAPSAISINE during the previous 3 months; * Patient with pacemaker; * Epileptic patient; * Patient with photosensitive medications, or any medical condition causing sensitivity to light (n.b., Lupus); * Pregnant and/or breastfeeding woman; * Patient with primary tumor and/or metastases in areas to be treated by BPM (i.e., hands and/or feet); * Patient with pre-existing eye disease (such as maculopathy, glaucoma, cataract and retinal lesions), or a history of family eye diseases; * Patient who has been already been treated with photobiomodulation on the area of interest. * Participation in another concomitant clinical study with neuropathic pain or chemo-induced peripheral neuropathy as the primary endpoint. * Presence of a tattoo on the area to be treated.